1.Immunotherapy for Advanced Pancreatic Cancer (Posted: 04/25/2006, Updated: 06/13/2008) - In this trial, researchers are using a monoclonal antibody called MDX-010 to treat patients with advanced pancreatic cancer. MDX-010 binds to and blocks the activity of an immune response inhibitor molecule called CTLA-4. 2.Adjuvant Biological Therapy for Pancreatic Cancer (Posted: 10/10/2006, Updated: 01/15/2008) - In this trial, patients with completely resected pancreatic cancer will receive adjuvant chemotherapy and radiation therapy plus additional treatment with either bevacizumab or cetuximab, monoclonal antibodies that target different proteins important for cancer growth and spread. 3.Gene Therapy for Metastatic Cancer (Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients. 4.Combination Therapy for Advanced Pancreatic Cancer (Posted: 08/16/2005) - In this study, researchers are adding a biological agent called bevacizumab (Avastin®) to standard chemotherapy with the drug gemcitabine to see if the combination can help improve the survival of pancreatic cancer patients whose disease has spread to nearby lymph nodes or to other sites in the body. 5.Targeted Combination Therapy for Advanced Solid Tumors (Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.
